Intermittent Versus Continuous Erlotinib with Concomitant Modified `Xelox' (Q3w) in First-Line Treatment of Metastatic Colorectal Cancer (Mcrc)

Trial Profile

Intermittent Versus Continuous Erlotinib with Concomitant Modified `Xelox' (Q3w) in First-Line Treatment of Metastatic Colorectal Cancer (Mcrc)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2013

At a glance

  • Drugs Erlotinib (Primary) ; Capecitabine; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 01 Oct 2013 Results published in Cancer.
    • 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
    • 01 Oct 2012 Primary endpoint 'Objective-clinical-response-rate' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top